Cargando…

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

BACKGROUND: A Multi Criteria Decision Analysis (MCDA) technique was adopted to reveal the preferences of the Appraisal Body of the Polish HTA agency towards orphan drugs (OMPs). RESULTS: There were 34 positive and 23 negative HTA recommendations out of 54 distinctive drug-indication pairs. The MCDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolasa, Katarzyna, Zwolinski, Krzysztof Miroslaw, Zah, Vladimir, Kaló, Zoltán, Lewandowski, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922020/
https://www.ncbi.nlm.nih.gov/pubmed/29703227
http://dx.doi.org/10.1186/s13023-018-0803-9
_version_ 1783318129542168576
author Kolasa, Katarzyna
Zwolinski, Krzysztof Miroslaw
Zah, Vladimir
Kaló, Zoltán
Lewandowski, Tadeusz
author_facet Kolasa, Katarzyna
Zwolinski, Krzysztof Miroslaw
Zah, Vladimir
Kaló, Zoltán
Lewandowski, Tadeusz
author_sort Kolasa, Katarzyna
collection PubMed
description BACKGROUND: A Multi Criteria Decision Analysis (MCDA) technique was adopted to reveal the preferences of the Appraisal Body of the Polish HTA agency towards orphan drugs (OMPs). RESULTS: There were 34 positive and 23 negative HTA recommendations out of 54 distinctive drug-indication pairs. The MCDA matrix consisted of 13 criteria, seven of which made the most impact on the HTA process. Appraisal of clinical evidence, cost of therapy, and safety considerations were the main contributors to the HTA guidance, whilst advancement of technology and manufacturing costs made the least impact. CONCLUSIONS: MCDA can be regarded as a valuable tool for revealing decision makers’ preferences in the healthcare sector. Given that only roughly half of all criteria included in the MCDA matrix were deemed to make an impact on the HTA process, there is certainly some room for improvement with respect to the adaptation of a new approach towards the value assessment of OMPs in Poland. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-018-0803-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5922020
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59220202018-05-07 Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis Kolasa, Katarzyna Zwolinski, Krzysztof Miroslaw Zah, Vladimir Kaló, Zoltán Lewandowski, Tadeusz Orphanet J Rare Dis Research BACKGROUND: A Multi Criteria Decision Analysis (MCDA) technique was adopted to reveal the preferences of the Appraisal Body of the Polish HTA agency towards orphan drugs (OMPs). RESULTS: There were 34 positive and 23 negative HTA recommendations out of 54 distinctive drug-indication pairs. The MCDA matrix consisted of 13 criteria, seven of which made the most impact on the HTA process. Appraisal of clinical evidence, cost of therapy, and safety considerations were the main contributors to the HTA guidance, whilst advancement of technology and manufacturing costs made the least impact. CONCLUSIONS: MCDA can be regarded as a valuable tool for revealing decision makers’ preferences in the healthcare sector. Given that only roughly half of all criteria included in the MCDA matrix were deemed to make an impact on the HTA process, there is certainly some room for improvement with respect to the adaptation of a new approach towards the value assessment of OMPs in Poland. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-018-0803-9) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-27 /pmc/articles/PMC5922020/ /pubmed/29703227 http://dx.doi.org/10.1186/s13023-018-0803-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kolasa, Katarzyna
Zwolinski, Krzysztof Miroslaw
Zah, Vladimir
Kaló, Zoltán
Lewandowski, Tadeusz
Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title_full Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title_fullStr Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title_full_unstemmed Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title_short Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
title_sort revealed preferences towards the appraisal of orphan drugs in poland - multi criteria decision analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922020/
https://www.ncbi.nlm.nih.gov/pubmed/29703227
http://dx.doi.org/10.1186/s13023-018-0803-9
work_keys_str_mv AT kolasakatarzyna revealedpreferencestowardstheappraisaloforphandrugsinpolandmulticriteriadecisionanalysis
AT zwolinskikrzysztofmiroslaw revealedpreferencestowardstheappraisaloforphandrugsinpolandmulticriteriadecisionanalysis
AT zahvladimir revealedpreferencestowardstheappraisaloforphandrugsinpolandmulticriteriadecisionanalysis
AT kalozoltan revealedpreferencestowardstheappraisaloforphandrugsinpolandmulticriteriadecisionanalysis
AT lewandowskitadeusz revealedpreferencestowardstheappraisaloforphandrugsinpolandmulticriteriadecisionanalysis